Bibliography
- Halfdanarson TR , RabeKG, RubinJet al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19, 1727–1733 (2008).
- Raymond E , DahanL, RaoulJLet al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
- De Bono JS , LogothetisCJ, MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
- Chapman PB , HauschildA, RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
- Robert C , ThomasL, BondarenkoIet al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
- Peck AR , WitkiewiczAK, LiuCet al. Loss of nuclear localized and tyrosine phosphorylated STAT5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J. Clin. Oncol. 29, 2448–2458 (2011).
- Schuster SJ , NeelapuSS, GauseBLet al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787–2794 (2011).
- Kardava L , MoirS, WangWet al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J. Clin. Invest. 121, 2614–2624 (2011).
Patents
- Winssinger N, Barluenger S, Karplus M. US0146545A1 (2008).
- Schneider M, Gottfreid M, Geisler J et al. US0056585A1 (2010).
Websites
- Merck completes acquisition of Inspire Pharmaceuticals, Inc. www.merck.com/newsroom/news-release-archive/corporate/2011_0516.html
- Merck Sharpe and Dohme completes Inspire takeover. www.zenopa.com/news_story.php?id=800535886
- Radius, 3M Drug Delivery Systems sign development agreement for transdermal drug delivery of BA058 for treatment of osteoporosis. http://solutions.3m.com/wps/portal/3M/en_WW/DrugDeliverySystems/DDSD/about-3M-Drug-Delivery/news/?PC_7_RJH9U5230O73F02RQG9R9E1OH0_assetId=1273684518958
- Sanofi and Glenmark Pharmaceuticals sign license agreement on novel monoclonal antibody for Crohn‘s disease and other chronic autoimmune disorders. http://en.sanofi.com/binaries/20110516_GLENMARK_en_tcm28–32720.pdf
- Glenmark Pharmaceuticals out-licenses novel monoclonal antibody, GBR500, to Sanofi. www.prnewswire.com/news-releases/glenmark-pharmaceuticals-out-licenses-novel-monoclonal-antibody-gbr-500-to-sanofi-121889273.html
- AVEO Pharmaceuticals enters into worldwide license agreement with Centocor Ortho Biotech to develop and commercialize RON-targeted antibodies. http://investor.aveopharma.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=1568940&highlight=
- Bristol-Myers Squibb and Roche enter into a clinical collaboration agreement to conduct combination studies with Yervoy™ (ipilimumab) and vemurafenib. www.bms.com/news/press_releases/pages/default.aspx
- Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer. www.roche.com/media/media_releases/med-cor-2011–2006–02.htm
- US FDA approves Yervoy (ipilimumab) for the treatment of patients with newly diagnosed or previously treated unresectable or metastatic melanoma, the deadliest form of skin cancer. www.bms.com/news/press_releases/pages/default.aspx
- Affectis Pharmaceuticals and Merck Serono announce an agreement to develop oral drugs for neurodegenerative diseases. www.affectis.com/attachments/030_Affectis-Merck%20Press%20Release%20080611_english.pdf
- Merck and Hanwha Chemical Corporation establish global strategic collaboration to develop and commercialize biosimilar candidate. www.merck.com/newsroom/news-release-archive/research-and-development/2011_0613.html
- Vertex and Alios BioPharma announce exclusive worldwide licensing agreement for two new nucleotide drug candidates, broadening Vertex‘s efforts to develop new combinations of medicines for hepatitis C. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=584023
- FDA approves Incivek™ for hepatitis C. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm
- FDA approves Edurant™ (rilpivirine) for use in treatment-naive adults with HIV-1. www.jnj.com/connect/news/all/fda-approves-edurant-rilpivirine-for-use-in-treatment-naive-adults-with-hiv-1
- FDA approves new HIV treatment. www.prnewswire.com/news-releases/fda-approves-new-hiv-treatment-122329203.html
- Sutent® receives FDA approval for advanced pancreatic neuroendocrine tumors. www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20110520006117en&source=RSS_2011&page=2
- FDA approves Incivek (telaprevir) for people with hepatitis C. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=580154
- FDA approves Incivek for hepatitis C. www.prnewswire.com/news-releases/fda-approves-incivek-for-hepatitis-c-122441703.html
- Abbott receives FDA approval for Xience nano™ to treat coronary artery disease in small vessels. www.abbott.com/PressRelease/2011May24.htm
- FDA approves Nulojix® for kidney transplant patients. www.prnewswire.com/news-releases/fda-approves-nulojix-for-kidney-transplant-patients-123944799.html
- FDA approves Nulojix (belatacept). www.bms.com/news/press_releases/pages/default.aspx?RSSLink=; http://www.businesswire.com/news/bms/20110616006683/en&t=634438393397918958
- Pivotal Phase 3 study published in The New England Journal of Medicine finds overall survival of patients with metastatic castration-resistant prostate cancer is significantly improved with Zytiga™ (abiraterone acetate). www.jnj.com/connect/news/all/phase-3-study-published-in-the-new-england-journal-of-medicine-finds-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-is-improved-with-zytiga
- Zytiga (abiraterone acetate) receives FDA approval for treatment of metastatic prostate cancer after priority review. www.jnj.com/connect/news/all/zytiga-abiraterone-acetate-receives-fda-approval-for-treatment-of-metastatic-prostate-cancer-after-priority-review
- Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations. www.roche.com/media/media_releases/med-cor-2011–2006–05.htm
- Plexxikon reports positive data from Phase 3 and Phase 2 trials of vemurafenib (PLX4032). www.daiichisankyo.com/news/detail/004093.html
- Genentech announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations. http://us1.campaign-archive2.com/?u=a79342281b0477b9894fca9da&id=36ce7d899e&e=9ea83021c8
- Second Phase III study of Yervoy (ipilimumab) in metastatic melanoma meets primary end point of overall survival. www.bms.com/news/press_releases/pages/default.aspx
- Merck and ARIAD announce presentation of results of Phase III SUCCEED trial at American Society of Clinical Oncology Annual Meeting. www.merck.com/newsroom/news-release-archive/research-and-development/2011_0606.html
- US patent granted for a new family of heat shock protein 90 (Hsp90) inhibitors for the treatment of cancer and neurodegenerative indications. www.nexgenixpharm.com/press/pr-2011–2005–19.html
- Syndax Pharmaceuticals announces issuance of US patent for entinostat. www.syndax.com/assets/110601_US_Patent.pdf
- Syndax Pharmaceuticals‘ entinostat plus erlotinib improves survival in select NSCLC patients. www.syndax.com/assets/12_9_10_ASTRO_Tarceva_plus_entinostat_shows_survival_advantage.pdf
- Marker identifies breast cancer patients likely to respond to tamoxifen. http://blog.kimmelcancercenter.org/?p=1884
- Vaccine increases disease-free survival for follicular lymphoma patients. www.medicalnewstoday.com/releases/227015.php
- NIH scientists reactivate immune cells exhausted by chronic HIV. www.niaid.nih.gov/news/newsreleases/2011/pages/sirna.aspx